Pharma Press Releases

Keep up to date with the latest technological developments happening across the Pharmaceutical industry. Our press releases can help you boost your online reach and exposure worldwide. Our Press releases provides information on the latest research in pharma.

Samsung Biologics and ImmuneOncia sign multi-product development and manufacturing agreement

Thursday, July 16, 2020

Samsung Biologics KS and ImmuneOncia Therapeutics held a signing ceremony for a contract to develop and manufacture five candidate molecules expanding upon the two companies existing CDO partnership first established in

Tevogen Bio Announces Steps Toward a Proprietary T Cell Therapy for Treatment of COVID-19 & Development of Bivalent Vaccine for COVID-19 & Influenza

Thursday, July 16, 2020

Tevogen Bio announces its intention to evaluate its proprietary antigenspecific T cell technology as a potential treatment for COVID patients

Brilinta significantly reduced the rate of the composite of stroke and death in patients who had an acute ischaemic stroke or transient ischaemic attack in the Phase III THALES trial

Thursday, July 16, 2020

Detailed results from the positive Phase III THALES trial showed AstraZenecas Brilinta ticagrelor mg used twice daily and taken with daily aspirin for days reduced the rate of the primary composite endpoint of stroke and death by HR CI p compar...

Novartis launches first-of-its-kind not-for-profit portfolio of medicines for symptomatic treatment of COVID-19

Thursday, July 16, 2020

Novartis announced a new initiative to help patients in lowincome and lowermiddleincome countries LIC LMIC access affordable medicines to treat the major symptoms of COVID a critical need in the absence of a vaccine or curative treatment Inflammatio...

Applied Biology and Kintor to Collaborate on the use of Proxalutamide for the Treatment of COVID-19

Wednesday, July 15, 2020

While studying the effects of androgens on hair loss Applied Biology scientists discovered an association between cellular receptors that predispose an individual to develop common hair loss androgenetic alopecia and COVID

FDA Grants Orphan Drug Designation for Inflazome’s Inzomelid for the Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)

Wednesday, July 15, 2020

Inflazome inflazomecom the pioneering inflammasome biotech company developing multiple drugs that stop harmful inflammation announces that it has been granted Orphan Drug Designation by the US Food and Drug Administration FDA for Inzomelid in the tre...

Byondis Initiates Phase II Study of Antibody-Drug Conjugate [Vic-]Trastuzumab Duocarmazine in Advanced Endometrial Cancer

Wednesday, July 15, 2020

Byondis BV formerly Synthon Biopharmaceuticals BV today announced that the first patients have started treatment in its Phase II study evaluating the safety and efficacy of its investigational antibodydrug conjugate ADC victrastuzumab duocarmazine SY...

European Commission approves third nintedanib indication in pulmonary fibrosis

Wednesday, July 15, 2020

Boehringer Ingelheim today announced that the European Commission EC has approved an additional indication for nintedanib in adults for the treatment of other chronic fibrosing interstitial lung diseases ILDs with a progressive phenotype beyond idiop...

Pfizer and BioNTech Granted FDA Fast Track Designation for Two Investigational mRNA-based Vaccine Candidates Against SARS-CoV-2

Tuesday, July 14, 2020

Pfizer Inc and BioNTech SE announced that two of the companies four investigational vaccine candidates from their BNT mRNAbased vaccine program BNTb and BNTb being developed to help protect against SARSCoV the virus that causes COVID received Fast T...

Rocket Pharmaceuticals Announces First Patient Treated in Phase 1 Trial of RP-L301 Gene Therapy for Pyruvate Kinase Deficiency

Tuesday, July 14, 2020

Rocket Pharmaceuticals Inc a clinicalstage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders announces that the first patient has received investigational therapy in the openlabel Phase clinic...

Eisai: Initiation of New Phase III Clinical Study (Ahead 3-45) of ban2401 Preclinical (Asymptomatic) Alzheimer's Disease

Tuesday, July 14, 2020

The Alzheimers Clinical Trials Consortium ACTC Eisai Co Ltd and Biogen Inc announced today that a new Phase III clinical study AHEAD of BAN an antiamyloid beta A protofibril antibody has been initiated in the United States of America for individuals...

Invivoscribe Launches New Division for Drug Development. Licenses Small Molecule Inhibitors from Domainex to Treat Acute Myeloid Leukemia

Tuesday, July 14, 2020

Invivoscribe Inc an industry pioneer and global leader in the field of precision diagnostics announces the launch of a fully integrated drug development engine This new engine will combine with its inhouse expertise in diagnostics development and wor...

Arch Biopartners Engages Global CRO to Conduct LSALT peptide (Metablok) Phase II trial for Treatment of Complications in COVID-19 Patients in the U.S.

Tuesday, July 14, 2020

Arch Biopartners Inc a clinical stage company developing new drug candidates for treating organ damage caused by inflammation today announced it has engaged a leading global contract research organization to initiate and conduct a Phase II trial in t...

Celyad Oncology Announces FDA Clearance of IND Application for CYAD-211, First shRNA-based, Non-Gene Edited Allogeneic CAR T Therapy

Tuesday, July 14, 2020

Celyad Oncology SA a clinicalstage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell CAR T therapies for cancer today announced that the companys Investigational New Drug IND application for CYAD the c...

SOTIO Announces First Patient Dosed in Part B of Phase 1/1b Study with SO-C101 in Combination with Pembrolizumab in Patients with Solid Tumors

Tuesday, July 14, 2020

SOTIO a clinical stage immunooncology company owned by PPF Group today announced that the first patient has been dosed in Part B of the ongoing Phase b study of IL superagonist SOC for the treatment of patients with advancedmetastatic solid tumors Pa...

Roche collaborates with Blueprint Medicines to bring a new treatment to people with RET-altered cancers

Tuesday, July 14, 2020

Roche and Blueprint Medicines Corporation today announced the signing of a licensing and collaboration agreement providing exclusive rights to Roche for global codevelopment and commercialisation outside the United States US excluding Greater China I...

GSK announces FDA advisory committee votes in favour of positive benefit/risk profile for belantamab mafodotin for patients with relapsed/refractory multiple myeloma

Tuesday, July 14, 2020

GlaxoSmithKline today announced the US Food and Drug Administration FDA Oncologic Drugs Advisory Committee ODAC voted in favour of the demonstrated benefit of monotherapy treatment with belantamab mafodotin outweighing the risks for patients with re...

TREMFYA® (guselkumab) Approved by U.S. Food and Drug Administration as the First Selective Interleukin (IL)-23 Inhibitor for Active Psoriatic Arthritis

Tuesday, July 14, 2020

The Janssen Pharmaceutical Companies of Johnson Johnson today announced that the US Food and Drug Administration FDA has approved TREMFYA guselkumab for adult patients with active psoriatic arthritis PsA a chronic progressive disease characterized b...

Spark Therapeutics Announces Updated Data on SPK-8011 from Phase 1/2 Clinical Trial in Hemophilia A at ISTH 2020 Virtual Congress

Monday, July 13, 2020

Spark Therapeutics a member of the Roche Group and a fully integrated commercial gene therapy company dedicated to challenging the inevitability of genetic disease today announced updated data from three dose cohorts of the ongoing Phase clinical t...

Luina Bio and XING Technologies set to manufacture new and fast SARS-CoV-2 diagnostic kit

Monday, July 13, 2020

Luina Bio is pleased to announce they have been selected to partner with XING Technologies Brisbane to codevelop and manufacture a Severe Acute Respiratory Syndrome Coronavirus SARSCoV diagnostic kit The COVID detection technology is based on a temp...

Eisai: Industry-Academia-Government Joint Development Agreement Aiming for Drug Discovery for Systemic Lupus Erythematosus by Practical Application of Toll-Like Receptor Research Concluded

Monday, July 13, 2020

Eisai Co Ltd announced today that it has entered into an industryacademiagovernment joint research agreement with four universities in Japan concerning the Industrialization of Japanoriginated Tolllike receptor research by AcademiaIndustry collaborat...

Roche provides update on Phase III study of Tecentriq in women with advanced stage ovarian cancer

Monday, July 13, 2020

Roche today announced that the Phase III IMagyn study showed that the addition of Tecentriq atezolizumab to Avastin bevacizumab paclitaxel and carboplatin did not meet its primary endpoint of progressionfree survival PFS for the frontline treatment o...

New data from phase IIIb study reinforces safety profile of Roche’s Hemlibra in people with haemophilia A

Monday, July 13, 2020

Roche today announced results from the second interim analysis of the phase IIIb STASEY study which reinforce the safety profile of Hemlibra emicizumab characterised in the phase III HAVEN clinical programme In the STASEY study Hemlibra was effective...

HemoShear Therapeutics Achieves Milestone in Exclusive Drug Discovery Collaboration with Horizon Therapeutics in Gout

Saturday, July 11, 2020

HemoShear Therapeutics LLC a privately held clinical stage biotechnology company has achieved a research milestone in its collaboration with Horizon Therapeutics plc to discover and develop novel therapeutics for gout In fewer than months HemoShears...

Tris Pharma and KYE Pharmaceuticals Announce Exclusive License Agreement to Commercialize Tris ADHD Products in Canada

Friday, July 10, 2020

Tris Pharma Inc Tris a specialty pharmaceutical company with a robust portfolio of FDAapproved products for the treatment of Attention Deficit Hyperactivity Disorder ADHD and related disorders and KYE Pharmaceuticals Inc KYE a private company headqua...

Assembly Biosciences Announces FDA Fast Track Designation Granted to ABI-H2158 for the Treatment of Chronic Hepatitis B Virus Infection

Friday, July 10, 2020

Assembly Biosciences Inc a clinicalstage biotechnology company developing innovative therapeutics targeting hepatitis B virus HBV and diseases associated with the microbiome announced that the US Food and Drug Administration FDA has granted Fast Tra...

Merck Opens its Largest M Lab™ Collaboration Center in Shanghai

Friday, July 10, 2020

Merck a leading science and technology company opened its M Lab Collaboration Center in Shanghai the companys largest of nine centers worldwide With the booming pharmaceutical industry in Asia and greater emphasis on novel drug therapies we see an in...

Gilead Presents Additional Data on Investigational Antiviral Remdesivir for the Treatment of COVID-19

Friday, July 10, 2020

Gilead Sciences Inc announced additional data on remdesivir an investigational antiviral for the treatment of COVID adding to the available body of knowledge on treatment outcomes with remdesivir The data are being presented at the Virtual COVID Conf...

Novartis Phase III IRIDIUM data in Lancet Respiratory Medicine show benefit of Enerzair® Breezhaler® (QVM149), the first-in-class inhaled LABA/LAMA/ICS combination in uncontrolled asthma

Friday, July 10, 2020

Novartis today announced that full results from the Phase III IRIDIUM study were published in The Lancet Respiratory Medicine The primary endpoint results show that oncedaily treatment with high and mediumdose Enerzair Breezhaler QVM indacaterol acet...

Concert Pharmaceuticals Receives FDA Breakthrough Therapy Designation for CTP-543 for the Treatment of Alopecia Areata

Thursday, July 09, 2020

Concert Pharmaceuticals Inc announced that the US Food and Drug Administration FDA granted Breakthrough Therapy Designation for the Companys oral Janus kinase inhibitor CTP for the treatment of adult patients with moderatetosevere alopecia areata The...